Reichardt P, Morosi C, Wardelmann E, et al. Gastrointestinal stromal tumors: evolving role of the multidisciplinary teamapproach in management[J]. Expert Rev Anticancer Ther, 2012, 12: 1053-1068.
[2]
Blay JY, Le CA, Cassier PA, et al. Gastrointestinal stromal tumors(GIST): a rare entity, a tumor model forpersonalized therapy, and yet ten different molecular subtypes[J]. Discov Med, 2012, 13: 357-367.
[3]
Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: astudy of 1840 cases[J]. Am J Surg Pathol, 2009, 33: 1401-1408.
[4]
Hwang DG, Qian X, Hornick JL. DOG1 antibody is a highly sensitive and specific marker for gastrointestinalstromal tumors in cytology cell blocks[J]. Am J Clin Pathol, 2011, 135: 448-453.
Faigel DO, Abulhawa S.Gastrointestinal stromal tumors: the role of the gastroenterologist in diagnosis and risk stratification[J]. J Clin Gastroenterol, 2012, 46:629-636.
[7]
Cavallaro G, Polistena A, Dermo G, et al. Duodenal gastrointestinal stromal tumors: review on clinical and surgicalaspects[J]. Int J Surg, 2012, 10: 463-465.
[8]
West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromaltumors irrespective of KIT or PDGFRA mutation status[J].Am J Pathol, 2004, 165:107-113.
[9]
Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker forgastrointestinal stromal tumors[J]. Am J Surg Pathol, 2008, 32: 210-218.
[10]
Dei TAP. The reappraisal of gastrointestinal stromal tumors: from Stout to the KITrevolution[J]. Virchows Arch, 2003, 442: 421-428.
